WWC
NBIX icon

Waypoint Wealth Counsel’s Neurocrine Biosciences NBIX Stock Holding History

Waypoint Wealth Counsel’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$230K Sell
1,363
-1,506
-52% -$223K 0.14% 125
2026
Q1 		$378K Sell
2,869
-431
-13% -$57.2K 0.2% 105
2025
Q4 		$468K Buy
3,300
+259
+9% +$37.5K 0.17% 114
2025
Q3 		$427K Buy
+3,041
New +$412K 0.17% 116

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Waypoint Wealth Counsel's NBIX Position: Q2 2026 in Review

Waypoint Wealth Counsel reduced its Neurocrine Biosciences (NBIX) stake by 52% in Q2 2026, selling an estimated $223K and leaving 1,363 shares worth $230K. The position accounts for 0.14% of the portfolio, ranked #125.

Waypoint Wealth Counsel first reported a position in NBIX in Q3 2025 and has held it in 4 quarters since. The position peaked at $468K in Q4 2025. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Waypoint Wealth Counsel held 1,363 shares of Neurocrine Biosciences worth $230K as of Q2 2026.
  • Waypoint Wealth Counsel sold 1,506 Neurocrine Biosciences shares in Q2 2026, an estimated $223K.
  • Neurocrine Biosciences made up 0.14% of Waypoint Wealth Counsel's portfolio in Q2 2026, its #125 holding.
  • Waypoint Wealth Counsel first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 4 quarters since.
  • Waypoint Wealth Counsel's Neurocrine Biosciences position peaked at $468K in Q4 2025.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Waypoint Wealth Counsel's 13F filing for Q2 2026, filed 4 Aug 2026.